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tasodilator Therapy
n Cardiac Failure
hat Was New Is Old
he paper by Mullens et al. (1) and editorial comment by Yancy
2) draw attention to use of vasodilators in treatment of acute and
hronic refractory cardiac failure. The importance of left ventric-
lar (LV) afterload is stressed, but this is described only in terms
f peripheral resistance as the ratio of mean arterial pressure and
ardiac output, with the latter requiring and justifying right heart
atheterization. There is a problem with this approach over and
bove the risks of Swan-Ganz catheter use; peripheral resistance is
nly part of LV afterload, which is best expressed as aortic input
mpedance (3,4). In addition to peripheral resistance, impedance
lso considers aortic stiffness and wave reflection, and the effects of
asodilator drugs on these (3–5). In the recent articles, brachial
ystolic pressure is taken as an index of LV afterload, but this is
onsiderably higher than aortic and LV systolic pressure, especially
n patients with cardiac failure and during use of vasodilators
4–6). Vascular impedance in cardiac failure during use of vaso-
ilator drugs is not mentioned in either article, but has been
escribed in major journals over the past 3 decades, and forms the
asis for modern treatment of this condition (3,4). Central aortic
ressure also can be estimated accurately through noninvasive
ethods (4,6), as can indices of arterial stiffness and wave
eflection (4,5).
Persons wishing to apply the principles described by Mullens
t al. (1) and Yancy (2) are advised to consider these issues. They
an measure LV afterload better, and avoid invasive catheterization
ompletely. They can also obtain a more accurate measure of mean
rterial pressure from integration of the arterial pressure waveform
sing applanation tonometry, rather than estimating this from the
naccurate formula of diastolic  one-third pulse pressure (4).
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eply
e thank Drs. O’Rourke and Nichols for their enthusiastic
nterest and insightful comments regarding our report on the
otential benefits of sodium nitroprusside (SNP) in the setting of
dvanced decompensated heart failure (ADHF) (1). We are in
omplete agreement regarding the many factors that influence left
entricular (LV) afterload, including the concept that aortic
mpedance can be a more integrated measure of LV afterload. We
ould like to emphasize that throughout the article there had not
een any assertion or assumptions that measuring systemic vascular
esistance in ADHF better reflects LV afterload compared with
ortic input impedance. It is also not the intention of our
etrospective case series to compare the effectiveness or safety of
dministration of SNP guided by a reduction in vascular resistance
r aortic input impedance. In fact, titration of SNP doses was
ased on achieving a measured target mean arterial blood pressure
f 65 to 70 mmHg and not on achieving a normal derived systemic
ascular resistance. Nevertheless, even with this relatively crude
ethod in the absence of specialized equipment, the substantial
mprovement in cardiac output secondary to sodium nitroprusside
herapy was associated with more favorable (rather than adverse)
ong-term outcomes. Although invasive measurements were used
n our protocol, it is not the intention of these data to always imply
he need for invasive monitoring, but solely to understand the
emodynamic contributors and subsequent changes induced by
odium nitroprusside during the treatment of ADHF. As with
nterpreting the clinical utility of any biomarker, there is an
mportant distinction between identifying individual patients who
ay have the appropriate hemodynamic profiles to benefit from a
pecific intervention versus using specific indexes of LV afterload
s targets of therapeutic interventions. We agree that much
romise exists regarding the use of noninvasive hemodynamic
onitoring. Nevertheless, in much the same way that pharmaco-
herapeutics require rigorous placebo-controlled testing in the
pecific population with the specific treatment goals to be certain
f benefit, diagnostic tools intended to guide therapy may require
he same validation, especially regarding use in the acutely ill heart
ailure population.
